Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

Circulating cell free DNA: Preanalytical considerations

(2013) Safia El Messaoudi et al.   CLINICA CHIMICA ACTA

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer

(2012) Mi-Jung Kim et al.   BMC CANCER

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens

(2012) D Gonzalez de Castro et al.   BRITISH JOURNAL OF CANCER

Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

(2012) K.-L. G. Spindler et al.   CLINICAL CANCER RESEARCH

The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients

(2012) Florent Mouliere et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment

(2012) Florence Boissière-Michot et al.   MODERN PATHOLOGY

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab

(2011) H Bando et al.   BRITISH JOURNAL OF CANCER

Circulating tumour markers can define patients with normal colons, benign polyps and cancers

(2011) R Mead et al.   BRITISH JOURNAL OF CANCER

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

(2011) N Knijn et al.   BRITISH JOURNAL OF CANCER

Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy

(2011) Satu Oltedal et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues

(2011) Jérome Solassol et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

High Fragmentation Characterizes Tumour-Derived Circulating DNA

(2011) Florent Mouliere et al.   PLoS One

Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer

(2011) Pedro Pinto et al.   Cancer Genetics

Prognostic Value of Circulating Mutant DNA in Unresectable Metastatic Colorectal Cancer

(2010) Benoit Lefebure et al.   ANNALS OF SURGERY

The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: A comparison between direct sequencing and real-time PCR

(2010) Takashi Kobunai et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

(2010) Ruth E. Board et al.   BREAST CANCER RESEARCH AND TREATMENT

The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients

(2010) N P West et al.   BRITISH JOURNAL OF CANCER

Colorectal cancer molecular biology moves into clinical practice

(2010) C. C. Pritchard et al.   GUT

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts

(2010) Alain R. Thierry et al.   NUCLEIC ACIDS RESEARCH

Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing

(2010) R. J. Leary et al.   Science Translational Medicine

Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

(2009) L.-C. Yen et al.   CLINICAL CANCER RESEARCH

The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments

(2009) S. A. Bustin et al.   CLINICAL CHEMISTRY

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

(2009) Frédéric Bibeau et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics

(2009) Wilko Weichert et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells

(2009) Junichi Soh et al.   PLoS One

Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients

(2008) Frank Diehl et al.   GASTROENTEROLOGY

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating mutant DNA to assess tumor dynamics

(2008) Frank Diehl et al.   NATURE MEDICINE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE